Drug Pipeline
31 drugs associated with Hemophilia B, severe
| Drug | Phase | Sponsor | |
|---|---|---|---|
Fibrinogen + PCC Fibrinogen exogenous protein | Approved | University Health Network, Toronto | ↗ |
Frozen Plasma | Approved | University Health Network, Toronto | ↗ |
ALN-AT3SC Antithrombin mRNA RNAi inhibitor | Phase 1 | Sanofi | ↗ |
BAY1093884 Tissue factor pathway inhibitor inhibitor | Phase 1 | Bayer | ↗ |
High dose KL001 | Phase 1 | Zhejiang University | ↗ |
Low dose KL001 | Phase 1 | Zhejiang University | ↗ |
Middle dose KL001 | Phase 1 | Zhejiang University | ↗ |
or early | Phase 1 | ||
approaches are | phase1_2 | ||
BAX 888 | Phase 2 | Baxalta now part of Shire | ↗ |
DTX101 | Phase 2 | Ultragenyx Pharmaceutical Inc | ↗ |
KN057 dose Ⅱ | Phase 2 | Suzhou Alphamab Co., Ltd. | ↗ |
KN057 dose Ⅲ | Phase 2 | Suzhou Alphamab Co., Ltd. | ↗ |
KN057 doseⅠ | Phase 2 | Suzhou Alphamab Co., Ltd. | ↗ |
LNP1265 | Phase 2 | Regeneron Pharmaceuticals | ↗ |
PF-06741086 Tissue factor pathway inhibitor inhibitor | Phase 2 | Pfizer | ↗ |
REGV131 | Phase 2 | Regeneron Pharmaceuticals | ↗ |
SerpinPC | Phase 2 | ApcinteX Ltd | ↗ |
AAV5-hFIXco-Padua Coagulation factor IX exogenous protein | Phase 3 | CSL Behring | ↗ |
BAX326 | Phase 3 | Baxalta now part of Shire | ↗ |